Supplementary Table 1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas

Supplementary Table 1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas

<p>Drug Screening Data</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Gerhard Jungwirth (15047922) (author)
Altres autors:	Tao Yu (15047925) (author), Fang Liu (15047928) (author), Junguo Cao (15047931) (author), Montadar Alaa Eddine (15047934) (author), Mahmoud Moustafa (15047937) (author), Amir Abdollahi (15026702) (author), Rolf Warta (15047940) (author), Andreas Unterberg (15047943) (author), Christel Herold-Mende (15047946) (author)
Publicat:	2025
Matèries:	Cancer Therapeutic Research and Development CNS Cancers Small Molecule Agents Translational Research
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Figure 2 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Figure 3 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Figure 4 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Figure 5 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Figure 6 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Figure 7 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Figure S1 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Figure S10 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Figure S2 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Figure S3 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Figure S4 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Figure S5 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Figure S6 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Figure S7 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Figure S8 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Figure S9 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Table 1 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
per: Emily E. Seiden (22436851)
Publicat: (2025)

Overview of 35 venom-derived peptide drugs, including their sequences, pharmacological activities, and regulatory status (FDA-approved or in clinical trials).
per: Rimsha Bibi (20405012)
Publicat: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
per: Francesca Orzan (15055579)
Publicat: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
per: Francesca Orzan (15055579)
Publicat: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
per: Francesca Orzan (15055579)
Publicat: (2025)

Supplemental Table 1 from Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine-Resistant Multiple Myeloma
per: Zachary J. Walker (19135313)
Publicat: (2025)

Supplemental Table 2 from Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine-Resistant Multiple Myeloma
per: Zachary J. Walker (19135313)
Publicat: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
per: Sied Kebir (15048732)
Publicat: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
per: Sied Kebir (15048732)
Publicat: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
per: Sied Kebir (15048732)
Publicat: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
per: Sied Kebir (15048732)
Publicat: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
per: Sied Kebir (15048732)
Publicat: (2025)

Figure 1 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
per: Elisa Izquierdo (15110795)
Publicat: (2025)

Figure 2 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
per: Elisa Izquierdo (15110795)
Publicat: (2025)

Figure 3 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
per: Elisa Izquierdo (15110795)
Publicat: (2025)

Figure 4 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
per: Elisa Izquierdo (15110795)
Publicat: (2025)

Figure 5 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
per: Elisa Izquierdo (15110795)
Publicat: (2025)

Figure 6 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
per: Elisa Izquierdo (15110795)
Publicat: (2025)

Figure 7 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
per: Elisa Izquierdo (15110795)
Publicat: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
per: William Kelly (15439117)
Publicat: (2025)

Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
per: William Kelly (15439117)
Publicat: (2025)

Supplementary Figure S1-S10 from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer
per: Imran Khan (15056870)
Publicat: (2025)

Supplementary Table 1 from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer
per: Imran Khan (15056870)
Publicat: (2025)

Supplementary Table 1 from Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase–mutant Astrocytic and Oligodendroglial Tumors
per: David Olayinka Kamson (16617218)
Publicat: (2025)